Citius Pharmaceuticals Inc. (CTXR)’s Financial Results Comparing With Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS)

Both Citius Pharmaceuticals Inc. (NASDAQ:CTXR) and Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Citius Pharmaceuticals Inc. N/A 0.00 12.54M -1.46 0.00
Sunesis Pharmaceuticals Inc. N/A 130.40 27.24M -0.80 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Citius Pharmaceuticals Inc. 0.00% -54.8% -49.6%
Sunesis Pharmaceuticals Inc. 0.00% 393.6% -103.8%


1.3 and 1.3 are the respective Current Ratio and a Quick Ratio of Citius Pharmaceuticals Inc. Its rival Sunesis Pharmaceuticals Inc.’s Current and Quick Ratios are 1.7 and 1.7 respectively. Sunesis Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Citius Pharmaceuticals Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Citius Pharmaceuticals Inc. and Sunesis Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Citius Pharmaceuticals Inc. 0 0 0 0.00
Sunesis Pharmaceuticals Inc. 0 1 0 2.00

Sunesis Pharmaceuticals Inc. on the other hand boasts of a $0.5 consensus price target and a -2.25% potential downside.

Insider and Institutional Ownership

Roughly 1.6% of Citius Pharmaceuticals Inc. shares are owned by institutional investors while 64.4% of Sunesis Pharmaceuticals Inc. are owned by institutional investors. About 50.8% of Citius Pharmaceuticals Inc.’s share are owned by insiders. Competitively, insiders own roughly 0.17% of Sunesis Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Citius Pharmaceuticals Inc. -6.84% -22.7% -23.57% -59.36% -77.8% -71.32%
Sunesis Pharmaceuticals Inc. -55.67% -70.37% -80.39% -83.54% -81.65% -89.16%

For the past year Citius Pharmaceuticals Inc.’s stock price has smaller decline than Sunesis Pharmaceuticals Inc.


Sunesis Pharmaceuticals Inc. beats Citius Pharmaceuticals Inc. on 5 of the 8 factors.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein BrutonÂ’s tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.